01 Increasing Sales and Demand for DNA Test Kits DNA testing kit sales have risen due to the steady demand for newborn screening.Key players have started advanced tests to maintain market competition and meet high demand. Ariosa Diagnostics, Sequenom, Natera, and Verinata Health (acquired by Illumina) are key players offering Non-invasive Prenatal Testing (NIPT) platforms in the U.S. The novel platforms utilize sequencing technologies, PCR, and proprietary algorithms to analyze Cell-free Fetal DNA (cffDNA) to detect chromosomal aneuploidies, such as Down's syndrome, Edwards' syndrome, and Patau syndrome. Other players, such as Ravgen, Cellular Research, and TrovaGene, have developed NIPT for chromosomal aneuploidies, driving the market growth.
02 Declining Sequencing Cost and Consequent Expansion of Genetic Testing Registry According to National Human Genome Research Institute (NHGRI), genome sequencing costs have been reduced by thousands of dollars over the past two decades, from USD 95,263,072 per genome in 2001 to USD 942 per genome in 2019. This has increased the adoption of genetic sequencing for early diagnosis and treatment of several disorders, including cancer and genetic variations of neurological conditions, cardiac disorders, and cystic fibrosis.The National Institutes of Health (NIH) developed Genetic Testing Registry (GTR) to enhance access to information on genetic tests. GTR is an online resource launched to centralize comprehensive information regarding genetic tests conducted across the globe. This initiative helped increase access to genetic information for pharmacogenetic tests and germline variations, subsequently increasing understanding of the importance of hereditary testing to prevent clinical disorders and further boost market growth.
01 Ethical and Clinical Issues of DNA Tests Ethical issues concerning the safety of in vitro fertilization and Preimplantation genetic diagnosis (PGD) are expected to hamper the market growth. PGD is morally unacceptable to several people and cultures as it is considered an unnatural creation and involves the destruction of human embryos. Application of these tests for sex selection on nonmedical backgrounds is prohibited in several countries, which is expected to restrain application demand and market growth.Furthermore, high implementation and procurement costs are major restraints for market growth in developing economies. The absence of an appropriate framework for insurance coverage and the accessibility of these tests are other factors expected to restrain growth. Miscoding, overbilling, and subsequent overpayment for genetic tests by insurance providers are further expected to hamper the market growth.
01 Growing Demand for Early and Non-Invasive Fetal Testing Procedures NIPT using cffDNA circulating in maternal blood can help detect common fetal trisomies, such as Down's syndrome, fetal Rhesus D status, and sex chromosome disorders. NGS-enabled clinical applications have witnessed considerable uptake over the past two years. The use of invasive procedures, such as amniocentesis and chorionic villus sampling, has declined over recent years, as non-invasive procedures are steadily being offered routinely at major treatment centers to all women with a high probability of having fetal genetic defects.NIPTs can be more accurate than current first-trimester screenings, resulting in fewer false positives, consequently reducing the number of invasive amniocenteses performed. Ongoing research can help expand the range of conditions detected through non-invasive means, including duplication/microdeletion syndromes and Mendelian genetic disorders. The use of test results for informed decision-making is expected to drive their adoption rate, creating hereditary testing market growth opportunities over the coming years.
April 2026 Illumina expanded its genomic testing technology initiatives by advancing sequencing platforms and solutions supporting hereditary disease detection. The company continued improving accuracy, scalability, and accessibility of genetic testing applications.
February 2026 Fulgent Genetics expanded its hereditary testing portfolio by strengthening genetic diagnostic services for inherited disorders and personalized healthcare applications. The company continued developing comprehensive testing solutions using advanced sequencing technologies.
January 2026 Invitae continued advancing hereditary genetic testing solutions through improvements in genomic analysis capabilities and clinical interpretation services. The company focused on supporting healthcare providers with expanded genetic insights for inherited conditions.
November 2025 Myriad Genetics expanded its genetic testing capabilities by advancing hereditary cancer testing solutions and clinical decision-support technologies. The company continued focusing on improving personalized healthcare through genomic information.
September 2025 Natera expanded its genetic testing platform by advancing molecular diagnostic technologies for inherited disease and personalized medicine applications. The company continued investing in improved genomic testing accuracy.
July 2025 Quest Diagnostics expanded its genetic testing services by strengthening hereditary disease screening and diagnostic capabilities. The company continued improving access to genomic testing through laboratory infrastructure expansion.